BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer

Completed · Phase 2

Conditions studied: Bladder Cancer

In brief

RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. Interferon alfa may interfere with the growth of cancer cells. Combining these therapies may be an effective treatment for bladder cancer. PURPOSE: Phase II trial to study the effectiveness of BCG plus interferon alfa 2b in treating patients who have bladder cancer.

Key facts

Study ID

NCT00004122

Run by

Roswell Park Cancer Institute

Starts

1999-07-01

Last updated by the study team

2013-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Roswell Park Cancer Institute — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.